CardioExchange Archive

AHA/ACC Publish Science Advisory on Thiazolidinedione Drugs: Apparently in response to the renewed controversy over rosiglitazone (Avandia), the AHA and the ACC published a science advisory on thiazolidinedione drugs and cardiovascular risks. The advisory contains a highly detailed and balanced analysis of the issue. The authors, led by Sanjay Kaul, conclude that “an association between rosiglitazone and IHD outcomes has not yet been firmly established,” but acknowledges that “sufficient evidence has emerged to raise concerns about a potential adverse effect.”

GlaxoSmithKline White Paper: GlaxoSmithKline published a 30 page White Paper in response to the Senate Finance Committee report released on Saturday. The senate report “mischaracterizes and distorts” GSK’s efforts to monitor the safety and efficacy of Avandia, the document claims.